PCM
PYXS icon

Prelude Capital Management’s Pyxis Oncology PYXS Stock Holding History

Prelude Capital Management’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,352
Closed -$20.6K – 1292
2023
Q3 		$20.6K Hold
10,352
– – ﹤0.01% 1070
2023
Q2 		$26.5K Buy
+10,352
New +$32.8K ﹤0.01% 1005
2022
Q4 		– Sell
-11,052
Closed -$22K – 1556
2022
Q3 		$22K Buy
+11,052
New +$28.9K ﹤0.01% 1269

Other funds holding PYXS

LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Prelude Capital Management's PYXS Position: Q4 2023 in Review

Prelude Capital Management sold out of Pyxis Oncology (PYXS) in Q4 2023, closing a stake of 10,352 shares — an estimated $20.6K sold.

Prelude Capital Management first reported a position in PYXS in Q3 2022 and held it in 3 quarters. The position peaked at $26.5K in Q2 2023. 51 funds tracked by Wall St. Rank hold PYXS as of Q4 2023.

  • Prelude Capital Management reported no remaining Pyxis Oncology position as of Q4 2023 after selling out during the quarter.
  • Prelude Capital Management sold 10,352 Pyxis Oncology shares in Q4 2023, an estimated $20.6K.
  • Prelude Capital Management first reported a position in Pyxis Oncology in Q3 2022 and held it in 3 quarters.
  • Prelude Capital Management's Pyxis Oncology position peaked at $26.5K in Q2 2023.
  • 51 funds tracked by Wall St. Rank held Pyxis Oncology as of Q4 2023.

Based on Prelude Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.